Acute portal vein thrombosis associated with chronic myeloproliferative neoplasm and subclinical hypothyroidism

References (10)

1. Condat B, Pessione F, Helene Denninger M, Hillaire S, Valla D. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology. 2000;32:466-70
2. DeLeve LD, Valla DC, Garcia-Tsao G; American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology. 2009;49:1729-64
3. Sekhar M, McVinnie K, Burroughs AK. Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol. 2013;162:730-47
4. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-61
5. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood. 2006;108:2435-7
6. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol. 2006;132:244-5
7. Squizzato A, Romualdi E, Piantanida E, Gerdes VE, Büller HR, Tanda M et al. Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study. Thromb Haemost. 2007;97:803-6
8. Hostiuc M, Curca GC, Dermengiu D, Sinescu C, Hostiuc S. Can subclinical hypothyroidism explain some sudden deaths due to pulmonary embolism without evident risk factors? Med Hypotheses. 2011;76:855-7
9. Hostiuc S, Capatina CO, Sinescu CJ, Hostiuc M. Lethal pulmonary thromboembolism associated with decreased thyroid hormone levels. Arch Endocrinol Metab. 2015;59:355-8
10. Segna D, Méan M, Limacher A, Baumgartner C, Blum MR, Beer JH et al. Association between thyroid dysfunction and venous thromboembolism in the elderly: a prospective cohort study. J Thromb Haemost. 2016;14:685-94.